Pioglitazone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Pioglitazone Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
621
Registered trials
218
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Pioglitazone Hydrochloride can convert its Small molecule drug profile and PPARγ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Pioglitazone Hydrochloride (query alias: Pioglitazone Hydrochloride) |
|---|---|
| Modality / target | Small molecule drug; PPARγ; PPARγ agonists |
| Highest global status | Approved |
| Originator | Takeda Pharmaceutical Co., Ltd. |
| Active developers | Takeda Pharmaceutical Co., Ltd., Actavis Group PTC ehf, Celltrion Healthcare Australia Pty Ltd. |
The MCP disease footprint includes Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07604779 | Not Applicable | Active, not recruiting | 150 | Fertilization rate |
| CTR20261401 | Not Applicable | 已完成 | 32 | Not disclosed |
| ChiCTR2600122952 | Not Applicable | Not yet recruiting | 30 | Change in the controlled attenuation parameter (CAP) from baseline to week 24 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude
Phase 4; n=9; evaluation: not stated. Reported fields: Rate of Exogenous Glucose Oxidation(Mean) = 0.32 g/min (Standard Deviation, 0.09); Rate of Exogenous Glucose Oxidation(Mean) = 0.31 g/min (Standard Deviation, 0.03); -
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
Phase 1/2; n=67; evaluation: not stated. Reported fields: Change in Stress-reactivity as Assessed by Heart Rate Change During the Cold Pressor Task (CPT)(Mean) = 5.138 beats per minutes (bpm) (Standard Deviation, 11.426); Change in Stress-reactivity as Assessed by Heart Rate Change During the Cold Pressor Task (CPT)(Mean) = 12.154 beats per minutes (bpm) (Standard Deviation, 11.885); -
Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)
Early Phase 1; n=14; evaluation: not stated. Reported fields: -; Baseline(Mean) = 2.9 score on a scale (Standard Deviation, 0.9); -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Pioglitazone Hydrochloride addresses Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 海森生物成功收购Celltrion公司14种品牌药品，加速推进泛亚太商业布局 | Approved | Financial terms not disclosed | |
| 2020-12-21 | CBC Group Announces the Completion of the Acquisition for 5 Takeda Drugs in the Cardiovascular & Metabolic Fields | Approved | US$322.0M stated total |
| Celltrion’s Subsidiary Acquires Primary Care Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company | Approved | US$278.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Method for improving dissolution rate of pioglitazone hydrochloride tablets”. The milestone feed surfaced a patent-application signal described as “Pioglitazone hydrochloride microneedle drug delivery system for treating type II diabetes and preparation method of pioglitazone hydrochloride microneedle drug delivery system”. The milestone feed surfaced a patent-application signal described as “Sampling device for pioglitazone hydrochloride and use method thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
